RxDoctor Payments Data

Robert Stein, MD

Vascular Neurology · Belfast, MENPI 1194704064

Payments from drug & device makers

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$1,131,288in research payments, 2019–2025

Across 48 payments — averaging $23,568 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.1M
  • Biogen$1K

How this compares

Too few vascular neurology providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$49,149
Medicare patients
286
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban920$1,108,535
XareltoRivaroxaban311$339,048
RebifInterferon Beta-1a/Albumin22$222,496
Aimovig AutoinjectorErenumab-Aooe29$54,076
Nurtec OdtRimegepant Sulfate24$28,949
UbrelvyUbrogepant12$15,076
Warfarin Sodium965$9,173
Carbamazepine ErCarbamazepine36$6,371
DilantinPhenytoin Sodium Extended52$5,876
Levetiracetam176$5,873
Divalproex Sodium31$4,871
Enoxaparin Sodium61$4,769
Carbidopa-LevodopaCarbidopa/Levodopa135$4,354
Memantine Hcl103$4,339
Gabapentin155$3,510

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Belfast

Where these figures come from

Is this you, or does something look wrong? →